腹主动脉旁预防延伸野放疗在局部晚期宫颈癌中的研究进展  

Research progress of para-aortic prophylactic extended-field irradiation in locally advanced cervical cancer

作　　者：王元景 吴玉梅[2] WANG Yuanjing;WU Yumei(Radiation Therapy Center,Beijing Obstetrics and Gynecology Hospital,Capital Medical UniversityBeijing Maternal and Child Health Care Hospital,Beijing 100006,China;Department of Gynecological Oncology,Beijing Obstetrics and Gynecology Hospital,Capital Medical UniversityBeijing Maternal and Child Health Care Hospital,Beijing 100006,China)

机构地区：[1]首都医科大学附属北京妇产医院北京妇幼保健院放疗中心,北京100006 [2]首都医科大学附属北京妇产医院北京妇幼保健院妇瘤科,北京100006

出　　处：《中国医药导报》2023年第5期42-46,共5页China Medical Herald

基　　金：北京市医院管理局重点医学专业发展专项经费资助项目(ZYLX201705);北京市科学技术委员会重点项目(Z191100006619035)。

摘　　要：宫颈癌是女性生殖系统最常见的恶性肿瘤。髂总或腹主动脉旁淋巴结阳性的局部晚期宫颈癌患者,推荐腹主动脉旁预防延伸野放疗。对于髂总或腹主动脉旁淋巴结阴性的患者,标准治疗依然是盆腔放疗联合同步铂类化疗。然而,腹主动脉旁淋巴结转移是局部晚期宫颈癌患者放化疗后治疗失败的常见原因之一。目前,针对存在腹主动脉旁淋巴结转移高危因素的患者,是否行预防延伸野放疗是存在争议的。本文从宫颈癌腹主动脉旁淋巴结转移的PET/CT评估价值、预防延伸放疗的有效性和适应证等方面进行综述,希望可以为宫颈癌个体化精准放疗提供重要参考。Cervical cancer is the most common malignancy of the female reproductive system.Para-aortic prophylactic extended-field irradiation is recommended for locally advanced cervical cancer patients with positive common iliac or para-aortic lymph nodes.For patients with negative common iliac or para-aortic lymph nodes,the standard treatment is still pelvic radiotherapy with concurrent cisplatin-based chemotherapy.However,para-aortic lymph node metastasis is one of the common causes of treatment failure in locally advanced cervical cancer patients after chemo-radiotherapy.Currently,it is controversial whether to perform prophylactic extended-field irradiation for patients with high-risk factors of para-aortic lymph node metastasis.This article reviews the value of PET/CT in evaluating para-aortic lymph node metastasis of cervical cancer,the effectiveness and indications of prophylactic extended-field irradiation,hoping to provide an important reference for individualized precision radiotherapy for cervical cancer.

关 键 词：局部晚期宫颈癌 PET/CT 放疗 预防延伸野放疗 淋巴结转移 

分 类 号：R737.33[医药卫生—肿瘤]